The drug, lecanemab, made by Eisai and Biogen, also carried risks of brain swelling and bleeding and should be studied further, a report of the findings said.
Alzheimer’s Drug May Benefit Some Patients, New Data Shows
The New York Times – Business:
This post first appeared in The New York Times – Business. Read the original article.
Written by
in